London, United Kingdom: The use of authorized medical cannabis products provides sustained improvements in patients suffering from chronic pain conditions, according to longitudinal data published in the Journal of Clinical Pharmacology.
British researchers assessed the use of botanical cannabis and oil extracts in 3,744 chronic pain patients enrolled in the UK Medical Cannabis Registry. (British healthcare specialists may prescribe cannabis-based medicinal products to patients unresponsive to conventional medications.) Researchers assessed changes from baseline in patient-reported outcomes at one, three, six, 12, 18, and 24 months.
Consistent with other studies, investigators reported “improvements … across every pain, health-related quality of life, anxiety, and sleep outcome, accompanied by a reduction in prescribed opioid burden and an adverse-event profile that was predominantly mild to moderate.”
Specifically, 23 percent of study participants who received opioids at baseline “achieved a clinically important reduction” in their opioid use by 24 months.
Separate longitudinal data published in September reported that pain patients authorized to use medical cannabis decrease their opioid intake by 90 percent over ten years.
The study’s authors concluded: “At the level of the whole cohort, treatment with CBMPs [cannabis-based medicinal products] was accompanied by improvements across every pain-specific measure. … The sustained improvement documented under real-world conditions remains of relevance to ongoing clinical practice.”
Other observational studies assessing the use of cannabis products among patients enrolled in the UK Medical Cannabis Registry have reported them to be beneficial for those diagnosed with endometriosis, treatment-resistant epilepsy, cancer-related pain, anxiety, hypermobility disorders/Ehlers-Danlos syndrome, inflammatory bowel disease, insomnia, migraine, multiple sclerosis, osteoarthritis, substance use disorders, and inflammatory arthritis, among other conditions.
Full text of the study, “Pain severity trajectories and patient profiles in chronic pain patients treated with cannabis-based medicinal products: A k-means clustering analysis of the UK Medical Cannabis Registry,” appears in the Journal of Clinical Pharmacology. Additional information on cannabinoids and chronic pain is available from NORML’s publication, Clinical Applications for Cannabis and Cannabinoids.
